One of the most common concerns South African patients have about GLP-1 weight loss medications is whether they are legal and regulated in this country. The short answer is yes — but the detail matters. This guide explains which medications are registered with SAHPRA (South Africa Health Products Regulatory Authority), which are prescribed off-label, and what each status means for your safety as a patient.
Key point: A medication being prescribed "off-label" does not mean it is illegal, experimental, or unsafe. Off-label prescribing by a qualified doctor is legal, common, and often supported by strong clinical evidence. The distinction is explained in full below.
SAHPRA is South Africa's national medicines regulatory authority. All medicines sold in South Africa must be either registered with SAHPRA or approved for use under specific regulatory provisions. SAHPRA evaluates a medication's safety, quality, and efficacy before allowing it onto the market.
Registration is granted for a specific indication — meaning the specific medical condition the medication is approved to treat. A medication can be registered for one indication (e.g., type 2 diabetes) but used by doctors for another (e.g., weight management). This is called off-label use.
Off-label prescribing occurs when a doctor prescribes a SAHPRA-registered medication for an indication, patient population, or dose that differs from the product's official registration. It is:
Ozempic is SAHPRA-registered as a treatment for type 2 diabetes. It is widely and legally prescribed off-label by South African doctors for weight management in patients who do not have diabetes. This off-label use is supported by the STEP clinical trial programme, which demonstrated 12–15% average body weight loss.
Off-label prescribing of Ozempic for weight loss is a routine, evidence-based practice that is accepted and commonly used by doctors across South Africa.
Mounjaro (tirzepatide) is registered with SAHPRA in South Africa. It can be prescribed by any HPCSA-registered doctor for appropriate patients. The dual GIP/GLP-1 mechanism makes it the most effective GLP-1 class medication currently available, with clinical trial data showing 20–22% average body weight loss.
Saxenda is SAHPRA-registered specifically for the management of obesity in adults with a BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Unlike Ozempic, Saxenda's weight management use is its primary registered indication — there is no off-label element. Saxenda requires a daily injection rather than weekly.
Wegovy is the high-dose formulation of semaglutide specifically developed for weight management. Wegovy (semaglutide 2.4 mg) is registered with SAHPRA in South Africa for the treatment of obesity. It is the dedicated weight management formulation of semaglutide — distinct from Ozempic, which is registered for diabetes and used off-label for weight loss.
Wegovy produces greater weight loss at its higher dose than the standard Ozempic doses, and its SAHPRA registration means the weight management indication is on the product label — there is no off-label element. South African patients who qualify can receive Wegovy as a registered treatment for obesity.
| Medication | Active Ingredient | SAHPRA Status | Type |
|---|---|---|---|
| Xenical / Orlistat | Orlistat | Registered | Lipase inhibitor (reduces fat absorption) |
| Contrave (not widely available) | Naltrexone + Bupropion | Check current status | CNS-acting combination |
| Topamax (topiramate) | Topiramate | Registered (epilepsy/migraine) — off-label for weight | Anticonvulsant with weight-reducing effect |
Choosing a medication that is SAHPRA-registered — or an off-label use supported by clinical evidence — ensures that:
Be cautious of any supplier, online retailer, or "clinic" offering GLP-1 medications without a valid prescription from a HPCSA-registered doctor. Unregistered or compounded versions of GLP-1 medications are not regulated by SAHPRA, carry unknown safety risks, and their use is not supported by Metabolic Doc.
Buyer beware: Compounded semaglutide injections (made by compounding pharmacies, often marketed as a cheaper alternative) have not been approved by SAHPRA and should not be used. Reports of adverse events from compounded GLP-1 products have emerged internationally. Always obtain your medication from a registered pharmacy with a valid SAHPRA-registered product.
Take our free 2-minute quiz to see if you're a good candidate for SAHPRA-approved GLP-1 therapy. Personalised result, no commitment.
Take the Free Quiz →